Tau Therapeutics
Tau Therapeutics engages in the R&D, repositioning and commercialization of calcium T-channel therapies for oncology and other diseases
About Tau Therapeutics
TauRx Therapeutics is a late-stage clinical biopharmaceutical company established in Singapore in 2002, with primary research operations in Aberdeen, Scotland. The company was co-founded by Professor Claude Wischik and the late K. M. Seng as a spin-out from the University of Aberdeen to develop treatments for neurodegenerative diseases. Wischik's journey in this field began in 1988 at Cambridge University, where he identified that the neurofibrillary tangles characteristic of Alzheimer's disease were composed of aggregated tau proteins. This foundational discovery led to further research and the eventual creation of TauRx to translate these findings into viable therapies.
The company's core business is the development and commercialization of treatments targeting the pathology of tau protein aggregation in the brain, a key factor in cognitive decline and neuronal death in diseases like Alzheimer's and frontotemporal dementia. Its business model revolves around advancing its drug candidates through rigorous clinical trials to gain regulatory approval and then commercializing these products in a multi-billion-dollar global market. The company has secured significant funding over several rounds to support its extensive research and development, raising a total of $434 million. A recent investment of $119 million was raised following positive results from its Phase 3 trial.
TauRx's lead product is Hydromethylthionine mesylate (HMTM), a second-generation Tau Aggregation Inhibitor (TAI) delivered as an oral tablet. This drug is designed to cross the blood-brain barrier to dissolve existing tau tangles and prevent the formation of new ones, thereby aiming to slow or halt the progression of neurodegeneration. Unlike many treatments that only manage symptoms, HMTM targets the underlying pathology of the disease. The company has completed its global Phase 3 LUCIDITY trial, which involved over 3,000 participants and has submitted HMTM for regulatory approval in the UK for treating mild cognitive impairment and mild to moderate Alzheimer's disease. The therapy's oral administration offers a more convenient and accessible option compared to intravenous treatments.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2014 | $13M | $51M | Undisclosed | — |
| SPINOUT✓Other financing | Jan 2003 | $0 | — | University of Virginia | — |
Growth signals
Latest recorded traffic for Tau Therapeutics is 170 monthly website visits. Tau Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tau Therapeutics in the Charlottesville ecosystem
The Tau Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Other known investors1 additional known investor
University of Virginia
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tau Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tau Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









